Ablepharon Macrostomia Syndrome

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting, February 12-16, in San Francisco. Among the topics presented: improved outcomes in computer-navigated and robot-assisted total knee replacements substantial reduction in post-operative complications in patients with significant weight loss before lumbar spinal fusion surgery an improved mental state after hip fracture repair surgery through an alternative method to general anesthesia in hip fracture repair surgery Understanding the differences in posterior tibial slope in unilateral versus bilateral ACL reconstruction "The faculty of our department are always focused on uncovering new, innovative ways to heal while improving the patient experience and outcomes," said Joseph D. Zuckerman, MD, FAAOS, the Walter A. L. Thompson Professor of Orthopedic Surgery, chair of the Department of Orthopedic Surgery at NYU Langone, and a former president of AAOS. "This year's impressive group of presentations at the nation's premier orthopedic meeting is a testament to why NYU Langone Orthopedics endeavors to always deliver world-class care to our patients." NYU Langone Orthopedics is ranked No. 4 in the nation by U.S. News and World Report, performing more than 34,000 orthopedic procedures annually by more than 200 orthopedic physician faculty. At this year's meeting, faculty of NYU Langone Orthopedics will present 39 posters, 31 e-posters, 34 papers, 31 videos, and 21 symposia, courses, specialty programs, and special sessions. Below are some of the notable presentations from this year's conference: Podium Presentation: Use of Technology Improves Short-Term Clinical Outcomes in Total Knee Arthroplasty The use of technology in total knee replacements, including computer-navigated and robot-assisted surgical systems, has increased in recent years, but the effect on patient-reported outcomes has been unclear. Surgeons at NYU Langone endeavored to determine short-term patient outcomes using these minimally invasive, precision-based technologies. "Technological innovations have enabled surgeons to improve implant positioning and accuracy, and we're seeing that positively impact the patient experience," said Morteza Meftah, MD, an associate professor of orthopedic surgery, a member of the Division of Adult Reconstructive Surgery at NYU Langone Orthopedics, and senior author of the study presented at AAOS. "The results indicate that not only are these technologies safe and effective, but they dramatically improve short-term outcomes of our patients having total knee surgery." The retrospective study by Dr. Meftah's group included a review of 16,009 NYU Langone surgeries from January 2017 to October 2023, comparing the use of computer-navigated and robotic surgical systems with conventional techniques in total knee arthroplasty. The results showed that length of stay was shorter and patients were discharged to their homes at a higher rate after either computer-navigated or robotic systems than they were after conventional methods. Additionally, perfect activity scores on post-operative discharge day zero were higher in robotic (30 percent) and navigated (19.5 percent) cases than the conventional group (8 percent). There were no differences in readmissions or revisions across any of the three surgical methods. Podium Presentation: Trimming the Risks: Weight Loss and its Effect on Obesity-Related Complications in Spine Fusion Surgery Although the benefits of weight reduction have been shown to improve overall health and satisfaction, the effect of preoperative weight loss on complications and outcomes after lumbar spinal fusion is not fully understood. Physicians in NYU Langone's Spine Center set out to evaluate the association of postoperative complications with significant weight loss prior to lumbar fusion surgery. "We wanted to understand if there are truly benefits to preoperative weight-loss programs ahead of spinal fusion surgeries, and found there were real differences," said Tina Raman, MD, study author and director of research for the Division of Spine Surgery at NYU Langone. "Our study confirmed a significant reduction in complication risk if patients lose weight before surgery. It's critical to have those conversations with patients and develop an effective plan leading up to surgery." In the study of 702 patients, including 362 with normal body mass index rates, 204 who were obese, and 136 who lost weight over an average of 1,896 days, significant differences were observed between the groups. Patients in the normal group had lower operative time, less blood loss, and shorter lengths of stay than patients who were obese, though there were no significant differences in those factors between the obese and weight loss groups. Deep surgical infections, however, were found to be significantly lower in the weight loss group (0 percent), compared with the group who were obese (3.45 percent). Podium Presentation: The Monitored Anesthesia Care–Soft Tissue Infiltration with Local Anesthesia (MAC–STILA) Technique Decreases Incidence of Short-Term Postoperative Altered Mental Status in Hip Fracture Patients Hip fractures are common injuries that have significant health impacts on patients, and altered mental status (AMS) from anesthesia is one of the most prevalent complications immediately following surgical repair. Those cognitive effects then have adverse impacts on outcomes, can delay rehabilitation, and increase costs for the hospital, insurance, and patient. Faculty set out to test an alternative approach to general anesthesia to see if AMS could be mitigated. "We want patients to be set up for the best recovery possible following surgery, so we looked at how to reduce altered mental status postoperatively," said Sanjit R. Konda, MD, an associate professor, a member of the Division of Trauma and Fracture Surgery, and senior author of the study presented at AAOS. "By using lighter sedation and adding local anesthetic at the hip-repair site, we saw a significant improvement in our patients after surgery." This technique, called monitored anesthesia care with soft-tissue infiltration with local anesthesia (MAC–STILA), pairs anesthesiologist-administered sedation with surgeon-administered local anesthetic applied directly on the surgical site. This alternative anesthesia approach can be used in hip fractures repaired with cannulated screws, sliding hip screws, and cephalomedullary nails. The study reviewed 1,076 procedures between October 2019 and November 2022 in which patients were given either MAC–STILA, general anesthesia (GA), or spinal anesthesia. The review found patients who had MAC–STILA had significantly lower odds of AMS in the short-term postoperative period compared with those who had GA. Additionally, MAC–STILA patients required significantly less narcotic medication up to 48 hours post-operatively compared to GA patients. American Orthopaedic Society of Sports Medicine Specialty Session: Patients with Bilateral ACL Reconstruction (ACLR) Have 3X the Rate of Posterior Tibial Slope Greater than 12-Degrees Compared to Unilateral ACLR: MRI and Radiographic Evaluation An increased posterior tibial slope (PTS)—a condition marked by a greater slope of the shin bone toward the back of the knee—can increase the risk of injury of the anterior cruciate ligament (ACL), the fibrous connective tissue in the knee that connects the shin bone to the thigh bone. Sports medicine physicians at NYU Langone Orthopedics will present findings on a study published in The American Journal of Sports Medicine that compares PTS values in patients who have undergone bilateral ACL reconstruction to those who had unilateral ACL reconstruction. "Understanding biomechanics and each patient's unique anatomy helps us to better manage their return to normal activity after surgery," said Laith M. Jazrawi, MD, chief of the Division of Sports Medicine. "Understanding the posterior tibial slope and the effect it has on the ACL can inform our approach to more individualized surgical repairs. We set out to determine if there is a much greater slope in patients who had bilateral ACL tears compared with patients who had a unilateral ACL tear." The retrospective compared radiography and magnetic resonance imaging (MRI) captured at NYU Langone among 53 patients who underwent unilateral ACL reconstruction and 53 patients who underwent bilateral ACL reconstruction between 2012 and 2020. The comparisons were matched between patients of similar age and body mass index and the same sex. Researchers found the rate of a radiographic PTS greater than 12 degrees was 2.4 times higher among patients who had bilateral ACL tears compared with those who had unilateral ACL tears. Additionally, when PTS measurement values on radiographs were compared with MRI, a negligible correlation was found between those two imaging modalities. Media Inquiries Marlene Naanes Phone: 929-923-3102 [email protected] Colin DeVries Phone: 212-404-3588 [email protected] SOURCE NYU Langone Health

YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI). The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI. The clinical trial (NCT02783482) GC5107B was a prospective, open-label, single-arm, historically controlled, multicenter phase 3 study to assess the efficacy and safety of GC5107B in patients with a confirmed diagnosis of PI. The studies were conducted in the United States and Canada. Key findings from the phase 3 clinical trial for patients aged 17 years and older include the following: A primary efficacy end point of 0.03 acute serious bacterial infections (aSBIs) per patient-year, which met the FDA efficacy requirement of less than one aSBI per patient-year. The proportion of infusions with temporally associated adverse events occurring during or within 72 hours after infusion was 0.22 (95% one-sided upper confidence bound: 30%), which met the FDA-required prespecified end point of less than 0.40. Secondary analyses were annual rate or days of other infections, antibiotic use, days out of work/school/day care or unable to perform normal activities due to infection, and days of hospitalization due to infection. ­­The results of the phase 3 trial by GC Biopharma are published in Frontiers in Immunology (2021). Dr. Elena Perez, MD., Allergy Immunologist from Allergy Associates of the Palm Beaches, and lead study investigator, said, "Alyglo will significantly impact clinical practice in the U.S. due to its strong safety and efficacy profile. It is an important treatment option for primary immune-deficient patients. This product provides additional confidence in treatment options for this important patient population." In addition, ALYGLO uses its novel Cation Exchange Chromatography (CEX) in the manufacturing process for removing coagulation factor XIa (FXIa) to undetectable levels. The presence of residual activated FXIa in some commercial IGIV products has been identified as the root cause of a small number of thromboembolic events in patients receiving immunoglobulin infusions. A recent study published in Frontiers in Cardiovascular Medicine details the extensive testing of ALYGLO and its results of the GC Biopharma manufacturing process. GC Biopharma is committed to evaluating how this new manufacturing process serves to further improve product safety. Dr. Eun-chul Huh, President and CEO of GC Biopharma, said, "The approval of ALYGLO by the US FDA is a significant milestone for GC Biopharma and patients with primary immunodeficiency disease. It reinforces GC Biopharma's commitment to patients and health care professionals by expanding our product portfolio globally to serve individuals with rare diseases. We are pleased to offer patients another important treatment option in the coming months that is both safe and effective." For any medical or scientific questions regarding ALYGLO, call the GC Biopharma USA medical department at 1-833-426-6426, or email [email protected]. About ALYGLO ALYGLO is a liquid solution containing 10% immunoglobulin G (100 mg/mL) for intravenous infusion, manufactured from pooled human plasma from US donors. The manufacturing process includes three steps to reduce the risk of virus transmission. These include fractionation, solvent/detergent treatment, and nanofiltration. ALYGLO also uses its novel Cation Exchange Chromatography (CEX) in the manufacturing process for removing FXIa to undetectable levels. About PI Primary Humoral Immunodeficiency (PI) refers to a group of disorders where the body's ability to produce antibodies is impaired, affecting the immune system's ability to fight infections. In PI, there's a deficiency or absence of B cells or plasma cells, which are key in producing antibodies, particularly immunoglobulin G. This leads to increased susceptibility to infection, especially bacterial infections affecting the respiratory and gastrointestinal tracts. People with PI might experience frequent infections, some of which can be severe or chronic. Treatment often involves immunoglobulin replacement therapy to boost the immune system. Vaccinations and antibiotics may also be used to prevent and treat infections. The exact type and severity of PI can vary widely among individuals. The PI indication for ALYGLO includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. About GC Biopharma Corp. GC Biopharma Corp. (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers lifesaving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is a leading global plasma protein and vaccine product manufacturer and has been dedicated to quality health care solutions for over half a century. About GC Biopharma USA, Inc. GC Biopharma USA, Inc., headquartered in Teaneck, NJ, established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on the expertise of our parent company, GC Biopharma's, expertise—a leading biopharmaceutical company delivering plasma therapies and vaccines worldwide. With GC Biopharma USA, Inc., GC Biopharma further extends its footprint, bringing its expertise and legacy to the United States. This press release may contain forward-looking statements that express the current beliefs and expectations of GC Biopharma Corp. management. Such statements do not represent any guarantee by GC Biopharma Corp. or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma Corp. undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. INDICATION ALYGLO™ is indicated for the treatment of primary humoral immunodeficiency (PI) in adults aged 17 years and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. IMPORTANT SAFETY INFORMATION WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Contraindications: ALYGLO is contraindicated in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Hypersensitivity: In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. Epinephrine should be available for immediate treatment of severe acute hypersensitivity reactions. Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. Aseptic Meningitis Syndrome (AMS): Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion. AMS usually begins within several hours to 2 days following ALYGLO treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae. Hemolysis: Delayed hemolytic anemia due to enhanced red blood cell (RBC) sequestration and acute hemolysis consistent with intravascular hemolysis have been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors. Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Patients with TRALI may be managed using oxygen therapy with adequate ventilator support. Monitor patients for pulmonary adverse reactions. Transmissible Infectious Agents: Because ALYGLO is made from human blood, it may carry a risk of transmitting infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent). Interference with Laboratory Tests: After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for a misleading interpretation. Adverse reactions (observed in ≥ 5% of study subjects) were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness. It is recommended that ALYGLO be administered separately from other drugs or medications. For more information about ALYGLO, please see full Prescribing Information. GC Biopharma Contact Seunghyun Baek [email protected] Sohee Kim [email protected] Yelin Jun [email protected] GC Biopharma USA Contact (Media) Robin Zvonek [email protected] (312) 636-5744 ©2023 GC Biopharma USA, Inc. All rights reserved. ALYGLO is a trademark of Green Cross Corporation. SOURCE GC Biopharma

Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business strategy focused on treating immunodeficiency disorders, which represent up to 55% of the total market for Ig, a category experiencing single-digit growth rates BARCELONA, Spain, July 20, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that its recently concluded phase 4 trial (NCT04566692) evaluating a biweekly dosing of XEMBIFY® has met its primary endpoint. It has demonstrated that patients with primary immunodeficiencies (PIDs) treated with this subcutaneous 20% immunoglobulin (SCIg) product every two weeks achieved non-inferiority in total Ig levels compared with those who received the medication weekly. The phase 4 trial also demonstrated similarly good safety and tolerability profiles between biweekly and weekly administration. It was a multicenter, single-sequence, open-label clinical study that included 27 subjects across 18 U.S. sites. Results will support the potential product labeling extension of XEMBIFY® to include biweekly dosing, pending review and approval by the United States Food and Drug Administration. This option is already available in the European markets where it is authorized. “Patients using XEMBIFY® could have an additional dosing option to choose from, providing more convenience and flexibility when controlling their immunodeficiencies,” said Kim Hanna, Grifols Senior Director Clinical Development. “Grifols is committed to strengthening its portfolio of leading immunoglobulin therapeutics to meet the growing demand as the number of people living with immunodeficiencies continues to increase.” With demonstrated efficacy and tolerability, XEMBIFY® is indicated for PIDs in the U.S. and both primary and select secondary immunodeficiencies (SIDs) in Europe, Canada and Australia. The global market for Ig is expected to grow in the high single digits in the coming years as a result of the increase in PIDs and SIDs, which together account for up to 55% of the total Ig market.1 SIDs have notably risen due to an aging population and the use of immunosuppressive therapies, such as immuno-oncology treatments, for which Ig is the preferred and only option. About XEMBIFY® Grifols XEMBIFY® is a 20% solution of purified human immunoglobulin (primarily immune globulin G [IgG]) made from large pools of human plasma via modifications of the Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C 10%) manufacturing process. INDICATION XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY® is for subcutaneous administration only. IMPORTANT SAFETY INFORMATION WARNING: THROMBOSIS Thrombosis may occur with immune globulin products, including XEMBIFY®. Risk factors may include: advanced age, prolonged immobilization, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factorsFor patients at risk of thrombosis, administer XEMBIFY® at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity Contraindications XEMBIFY® is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity. Warnings and Precautions Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY®. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY®. Thrombosis may occur in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY®. Conduct a thorough neurological exam on patients exhibiting signs and symptoms to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae. Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY® does not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function prior to the initial infusion of XEMBIFY® and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation. Hemolysis. XEMBIFY® may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing. Transfusion-related acute lung injury (TRALI). Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY®. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support. Transmissible infectious agents. Because XEMBIFY® is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD, or CJD have ever been associated with the use of XEMBIFY®. Interference with lab tests. After infusion of XEMBIFY®, passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Adverse Reactions The most common adverse reactions in ≥ 5% of subjects in the clinical trial were local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea. Drug InteractionsPassive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see full Prescribing Information for XEMBIFY® or visit www.xembify.com Globally, prescribing information varies; refer to the individual country product label for complete information. About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2022, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit www.grifols.com MEDIA CONTACT: Media Press Officemedia@grifols.comTel. +34 93 571 00 02 INVESTORS: Investors Relations Department & Sustainabilityinversores@grifols.com - investors@grifols.com Tel. +34 93 571 02 21 LEGAL DISCLAIMER The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group. 1 Marketing Research Bureau. Global Usage and Forecast of the Immunoglobulin Market by Region